LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

Trailhead Biosystems expands iPSC-derived portfolio with TrailBio Hematopoietic Progenitor Cells: Beachwood, Ohio Wednesday, August 6, 2025, 16:00 Hrs [IST] Trailhead Biosystems, ...

It is already well-known that when a mother experiences inflammation during pregnancy, her child is more likely to develop ...

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...

This study reports important negative results by showing that genetic removal of the RNA-binding protein PTBP1 in astrocytes is not sufficient to induce their conversion into neurons, challenging ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

This article explains how aluminum adjuvants work in vaccines, their proven safety record, and addresses common myths and ...

Researchers at Kyoto University have discovered that an immune molecule found only in primates, called IGFL2, plays a key ...

Senior author and evolutionary biology professor Eamonn Mallon explained: "It’s like the wasps who took a break early in life ...

Novel allogeneic stem cells and differentiated iPSCs are providing more physiologically relevant disease models.

These soluble protein agonists can replicate Notch activation in suspension culture, opening the door to scalable T-cell therapies.